Search Browse Earnings

Avalo Therapeutics, Inc. — SlamSEC

Avalo Therapeutics, Inc.

Nasdaq:AVTX

Pharmaceutical Preparations·WAYNE, PA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$1.9M

-89.3% YoY

FY 2024

Adj. EBITDA

-$27.2M

-1413.4% margin

FY 2024

Net Income

-$31.5M

-1639.5% margin

FY 2024

EPS (Diluted)

-$113.58

FY 2024

Stock Price

$17.47

-0.6%

2026-03-09

52W Range

$3.39 – $20.72

P/E Ratio

-0.2x

Market Cap

$316.8M

Cash

$7.4M

FY 2024

Total Debt

$5.9M

FY 2018

Net Cash

$1.5M

FY 2018

Enterprise Value

$315.3M

Debt / EBITDA

0.1x

FY 2024

EV / EBITDA

-11.6x

Employees

—